Eton Pharmaceuticals, Inc. (ETON)
Thursday, November 5, 2026
Key stats
Chart
Price, buy and sell signals and key levels on one chart.
Past 1Y
MA21MA180
SignalsBuyEarly buySellEarly sellTurning pointsSwing highSwing low
Up dayDown day
Thursday, November 5, 2026
Price, buy and sell signals and key levels on one chart.
Eton Pharmaceuticals (ETON) closed at $50.72 on Nov 4, 2026, down 0.5% on the day. The stock is down 7.4% over the past month, up 9.8% over three months, up 199.9% year to date and up 174.9% over the past year (since Nov 4, 2025). It trades 23.6% below its 52-week high of $66.37 and 255.4% above its 52-week low of $14.27. The close sits below its 50-day moving average ($55.24) and above its 200-day moving average ($36.24).
ETON is scheduled to report earnings on Nov 5, 2026, after market close.
Eton Pharmaceuticals is scheduled to report on Nov 5, 2026, after market close.
Yes — the Nov 4, 2026 close of $50.72 is 40.0% above the 200-day average of $36.24.
ETON closed 23.6% below its 52-week high of $66.37.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.